The PubMed entry identifies the study as the platform trial in COVID-19 priming and BOOsting (PICOBOO) examining reactogenicity following administration of nine licensed COVID-19 vaccines to immunocompetent adults. The trial is recorded as a randomized controlled trial and published in Vaccine (2026) with DOI 10.1016/j.vaccine.2026.129034. Investigators and multi-institutional authorship were listed, including Australian vaccine research centres and collaborating institutions in the United Kingdom. The source therefore establishes the trial’s existence and journal publication details, but it does not reproduce the study’s abstract text containing numerical outcomes in the excerpt provided.
The PubMed summary labels the study focus as reactogenicity across nine licensed vaccines. The displayed record did not, however, include itemized results: there are no frequencies, no severity gradings, and no head-to-head comparative statistics shown in the excerpt. The study team’s observations, as presented in the PubMed view available here, are limited to the trial title and metadata; the specific reactogenicity endpoints and outcome figures are not present in the source text provided. Clinicians seeking outcome data must consult the full text linked by DOI for the complete results table and any comparative analyses.
The PubMed record does not enumerate individual adverse events, rates of solicited local or systemic reactions, or occurrences of serious adverse events in the excerpt shown. The listing identifies this work as a randomized controlled platform trial addressing tolerability, yet the source did not report specific safety signals or describe event attribution or temporal patterns. The absence of these details in the displayed entry prevents direct clinical appraisal of which vaccines showed higher reactogenicity or whether particular unexpected safety findings occurred.
The PubMed metadata confirms randomized controlled platform design and authorship, but it omits critical methodological parameters in the excerpt: sample sizes, participant age ranges, inclusion and exclusion criteria, randomization procedure, blinding status, dosing schedules, interval between doses or boosters, and prespecified primary and secondary endpoints were not provided. Data on statistical methodology, safety monitoring processes, and prespecified subgroup analyses were likewise absent from the displayed record. The source therefore documents that a formal trial was conducted but does not furnish the granular trial design and analytic plan needed to interpret results directly from this entry.
The article citation indicates publication in Vaccine (2026 Oct 24:92:129034), with an earlier online posting (Epub 2026 Sep 5) and a DOI for retrieval. The PubMed entry supplies author names, affiliations, PMID (42700749), and DOI, enabling access to the publisher’s full text. For clinicians and researchers who require the numeric reactogenicity outcomes, stratified safety data, or methodological appendices (for example, trial protocol or statistical analysis plan), the full article at the journal site—accessible via the provided DOI—must be consulted. The PubMed excerpt does not substitute for the primary manuscript.
The primary limitation of the PubMed record, as displayed, is omission: the excerpt lacks the actual abstract text and outcome data. Consequently, readers cannot extract event rates, comparative reactogenicity profiles, or prespecified endpoints from the source shown here. The record does not provide the trial’s sample size, demographic breakdown, or detailed methods. Because these critical details are not present in the PubMed excerpt, any clinical interpretation based on this source alone would be incomplete. The full manuscript is the authoritative source for outcomes, and clinicians should retrieve it for definitive figures, subgroup findings, and the authors’ own interpretation and discussion.
Practical next steps for clinicians and researchers: consult the Vaccine article via DOI 10.1016/j.vaccine.2026.129034 to review the complete methods, tables of reactogenicity and safety outcomes, and any supplementary materials such as the trial protocol or dataset descriptions. The PubMed entry reliably conveys study existence, authorship, and publication metadata, but it does not present the empirical results required for evidence-based comparative assessments of reactogenicity across the nine licensed COVID-19 vaccines evaluated in PICOBOO.